Increased apolipoprotein E and decreased TNF-α in the cerebrospinal fluid of nondemented APOE-ε4 carriers

Daimei Sasayama1,2,3 | Kotaro Hattori1,4 | Yuuki Yokota1,4 | Ryo Matsumura4 | Toshiya Teraishi1 | Sumiko Yoshida4,5 | Hiroshi Kunugi1,6

1Department of Mental Disorder Research, National Center of Neurology and Psychiatry, National Institute of Neuroscience, Kodaira, Japan
2Department of Psychiatry, Shinshu University School of Medicine, Matsumoto, Japan
3Child and Adolescent Developmental Psychiatry, Shinshu University School of Medicine, Matsumoto, Japan
4Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Japan
5Department of Psychiatry, National Center of Neurology and Psychiatry, National Center Hospital, Kodaira, Japan
6Department of Psychiatry, Teikyo University School of Medicine, Itabashi-ku, Japan

Correspondence
Hiroshi Kunugi, Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawahigashi, Kodaira, Tokyo 187-8502, Japan.
Email: hkunugi@ncnp.go.jp

Funding information
This work was supported by Intramural Research Grant [27-1, 27-6, 30-3] for Neurological and Psychiatric Disorders of National Center of Neurology and Psychiatry (HK and KH), Grant-in-Aid for Scientific Research (A) [25253075] from the Ministry of Education, Science, Sports and Culture, (HK and KH), and Funding for research to expedite effective drug discovery by Government, Academia and Private partnership [17ak0101044h0402] from the Japan Agency for Medical Research and Development, AMED.

Abstract
Aim: The ε4 allele of apolipoprotein E gene (APOE) is a well-known risk factor of late-onset Alzheimer's disease. However, little is known why this variant confers a risk for Alzheimer's disease. The aim of this study was to examine the influence of the APOE genotype on cerebrospinal fluid (CSF) protein levels.

Methods: The present study performed a secondary analysis on our previously generated database to compare the CSF levels of 1128 proteins between APOE-ε4 carriers (28 subjects) and noncarriers (104 subjects). All subjects were physically healthy Japanese individuals without dementia.

Results: CSF levels of apoE2, apoE3, and apoE4 were significantly higher (all nominal \( P < 10 \times 10^{-5} \), false discovery rate < 0.001) and those of tumor necrosis factor-α (TNF-α) were significantly lower (nominal \( P = 1.39 \times 10^{-6} \), false discovery rate < 0.001) in APOE-ε4 carriers than in noncarriers. No significant correlation was observed between the CSF levels of TNF-α and any of the apoE proteins.

Conclusions: Our findings indicate the possible roles of apoE and TNF-α in the pathogenesis of APOE-ε4-associated Alzheimer's disease.

KEYWORDS
alzheimer disease, apolipoproteins E, biomarkers, cerebrospinal fluid proteins, tumor necrosis factor-alpha
1 | INTRODUCTION

The apolipoprotein-E (APOE) encodes the protein apolipoprotein E (apoE), which plays a role in lipid transport. Common allelic variants of APOE are ε2, ε3, and ε4, which are determined by the two SNPs rs429358 and rs7412. The ε4 allele of APOE is the largest genetic risk factor known to date for late-onset (sporadic) Alzheimer’s disease (AD). However, little is known regarding its mechanism of action in conferring the risk for AD.

Cerebrospinal fluid (CSF) biomarkers have been well established for the diagnosis of AD. Low levels of amyloid β, and high levels of total tau and phosphorylated tau in CSF have been identified as the core biomarkers for AD. Several synaptic proteins and inflammatory markers in CSF have also been implicated as possible biomarkers. CSF is practically the only accessible source of proteins derived from the central nervous system (CNS) of living human subjects. Therefore, focusing on CSF proteins might provide an important clue for disentangling the pathophysiological processes of AD. In the present study, we examined the possible association of the APOE-ε4 allele with CSF protein levels in nondemented subjects. This is the second analysis of our CSF proteomics by a genome-wide genotyping database.

2 | METHODS

Subjects were 132 Japanese individuals (68 men and 64 women; mean age [standard deviation] = 42.1 [11.7] years) whose data of 1128 CSF proteins and the genotypes of rs7412 and rs4420638 were retrieved from the database of our previous study. The SNP and protein data from this study can be accessed at NCBI GEO (http://www.ncbi.nlm.nih.gov/geo) under accession number GSE83711. Although the allelic variants of APOE are defined by rs429358 and rs7412, the genotype data of rs429358 were not available in our database. Therefore, rs4420638, which is included in the database and is in complete linkage disequilibrium with rs429358 (D′ = 1, R² = .86 in a Japanese population), was used to determine the allelic variants of APOE. According to LDLink, the A allele of rs4420638 is completely associated with the T allele of rs429358, and 89% of the G allele of rs4420638 corresponds to the C allele of rs429358. The numbers of subjects for each predicted genotype of APOE are shown in Table S1. The CSF levels of apoE2, apoE3, apoE4, and tumor necrosis factor-α (TNF-α) were significantly different between APOE-ε4 carriers and noncarriers after correcting for multiple comparisons using FDR. As shown in Figure 1, apoE2, apoE3, and apoE4 were significantly higher, while TNF-α was significantly lower in APOE-ε4 carriers than in noncarriers. The CSF levels of the proteins were significantly different depending on APOE genotype. The CSF levels of apoE2, apoE3, and apoE4 were significantly correlated with each other (all Spearman’s ρ > 0.9 and P < .0001). However, the CSF levels of TNF-α were not significantly correlated with any of the apoE proteins (all P > .05). As shown in Table 2, the CSF levels of TNF-α were significantly higher in women than in men (P = .040), and apoE2, apoE3, and apoE4 levels showed a significantly negative correlation with age (all P < .01).

Because the study subjects included 87 patients with psychiatric disorders, we next compared the CSF protein levels between subjects for each predicted genotype of APOE. These are shown in Table 1. The complete results of the Mann-Whitney U test comparing 1128 CSF protein levels between APOE-ε4 carriers and noncarriers are shown in Table S1. The CSF levels of apoE2, apoE3, apoE4, and tumor necrosis factor-α (TNF-α) were significantly different between APOE-ε4 carriers and noncarriers. The CSF levels of apoE2, apoE3, and apoE4 were significantly correlated with each other (all Spearman’s ρ > 0.9 and P < .0001). However, the CSF levels of TNF-α were not significantly correlated with any of the apoE proteins (all P > .05).

As described previously, most subjects had participated in other studies, which examined the CSF protein levels in patients with psychiatric disorders (n = 87). All participants were physically healthy and without clinically significant systemic disease. None of the participants were diagnosed with dementia. All subjects were biologically unrelated Japanese individuals. The genotypes were examined using the Illumina HumanOmni1-Quad BeadChip (Illumina, Inc). The proteomic assessments were performed by SomaLogic Inc as described elsewhere. The study protocol was approved by the ethics committee at the National Center of Neurology and Psychiatry, Japan. Informed consent for study participation was obtained from every subject.

All statistical analyses were performed using the R software version 3.4.0 (https://cran.r-project.org/). Differences in age and sex between APOE-ε4 carriers and noncarriers were compared using a t test and chi-square test, respectively. A Mann-Whitney U test was used to compare protein levels between APOE-ε4 carriers and noncarriers. Difference in CSF levels between groups was considered significant at the false discovery rate (FDR) of < 0.01. FDR was calculated according to Benjamini and Hochberg’s method. Correlation between CSF protein levels was assessed using Spearman’s correlation coefficients.

| rs7412 | rs4420638 | Predicted genotype | Number of subjects |
|--------|-----------|--------------------|--------------------|
| (T;T)  | (G;G)     | ApoE-ε1/ε1         | 0                  |
| (T;T)  | (G;A)     | ApoE-ε1/ε2         | 0                  |
| (C;T)  | (G;A)     | ApoE-ε1/ε3 or ApoE-ε2/ε4 | 0                  |
| (C;T)  | (G;G)     | ApoE-ε1/ε4         | 0                  |
| (T;T)  | (A;A)     | ApoE-ε2/ε2         | 0                  |
| (C;T)  | (A;A)     | ApoE-ε2/ε3         | 9                  |
| (C;C)  | (A;A)     | ApoE-ε3/ε3         | 95                 |
| (C;C)  | (G;A)     | ApoE-ε3/ε4         | 27                 |
| (C;C)  | (G;G)     | ApoE-ε4/ε4         | 1                  |

Abbreviation: ApoE: apolipoprotein E.
ApoE-ε4 carriers and noncarriers separately in psychiatric patients and psychiatrically healthy subjects to examine whether a psychiatric disorder influenced the effect of APOE genotypes on CSF protein levels. Mann-Whitney U tests showed that CSF levels of apoE2, apoE3, apoE4, and TNF-α were significantly higher in APOE-ε4 carriers than in noncarriers (all P < .0001, Mann-Whitney U test). TNF-α was significantly lower in APOE-ε4 carriers than in noncarriers (P < .0001, Mann-Whitney U test). The number of subjects in each genotype is as follows. ε4/ε4: healthy subjects (n = 0), psychiatric patients (n = 1). ε3/ε4: healthy subjects (n = 10), psychiatric patients (n = 17). ε3/ε3: healthy subjects (n = 31), psychiatric patients (n = 64). ε2/ε3: healthy subjects (n = 4), psychiatric patients (n = 5). ***P < .0001

4 | DISCUSSION

The present study is the first proteome-wide analysis to examine the influence of APOE-ε4 alleles on CSF protein levels in nondemented
subjects. Our findings showed that carrying the APOE-ε4 allele is associated with increased apoE2, apoE3, and apoE4, as well as decreased TNF-α levels in the CSF. The difference between APOE-ε4 carriers and noncarriers remained robustly significant even after correcting for multiple comparisons.

Contrary to our findings, some previous studies reported no significant difference in total CSF apoE concentrations between APOE-ε4 carriers and noncarriers. Furthermore, Cruchaga et al. reported that the total apoE levels in the CSF were lower in APOE-ε4 carriers than in noncarriers, irrespective of the presence of AD. However, consistent with our findings, Darreh-Shori et al. reported a low correlation between apoE protein levels and carriers with AD carrying the APOE-ε4 allele, in an ε4 dose-dependent manner. One reason for the inconsistencies between study results may be the small number of subjects in some studies reporting negative findings. Another reason may be the difference in the apoE quantification methods. Indeed, Cruchaga et al. reported a low correlation between apoE levels measured in different assays. However, we believe that our findings are reliable because the CSF protein levels recorded in the database were measured by a highly sensitive analysis using SOMAmer reagents with high affinity and specificity for their target proteins. The low intra-assay coefficient of variation previously reported for SOMAmer assay (6.1%, 5.8%, 8.1%, and 2.5% for apoE2, apoE3, apoE4, and TNF-α, respectively) also indicates the good precision of the assay system. Furthermore, this study is useful in that it is the first, to our knowledge, to examine the CSF levels of each apoE isoform to investigate the association with the APOE genotypes.

The significantly negative correlations observed in the present study between age and each apoE level contradict with previous findings showing a positive correlation between age and CSF apoE levels. A possible explanation for the inconsistency may be that we did not include patients with AD in our study. Future studies are necessary to elucidate the influence of aging on the CSF levels of apoE.

The present study is also the first, to our knowledge, to report that TNF-α levels in the CSF are decreased in APOE-ε4 carriers. Our result seems to contradict previous findings that TNF-α plays a role in the pathophysiology of AD by enhancing amyloid beta production. Indeed, a previous study reported that TNF-α was elevated in the blood and CSF of patients with AD. However, in vitro data suggest that TNF-α may exert a neuroprotective effect by stimulating neuronal cells to express bcl-2, which may explain the elevated risk of developing AD in APOE-ε4 carriers with decreased TNF-α levels. Further investigations are necessary to clarify the role of decreased TNF-α in increasing the risk for AD in APOE-ε4 carriers.

Regard the association with apoE, TNF-α secretion induced by lipopolysaccharide stimulation was inhibited by preincubation with apoE in glial cells. Conversely, ApoE gene-knockout in mice resulted in high expressions of cytokines, including TNF-α in the brain. These findings are consistent with our results that subjects with high apoE-expressing genotypes had lower CSF TNF-α levels. However, no significant correlation between apoE and TNF-α levels was observed. Several possibilities may be considered for the lack of significant correlation between apoE and TNF-α levels; for example, APOE-ε4 alleles may function to decrease TNF-α levels through a mechanism independent of apoE proteins, or TNF-α levels may not adequately reflect the fluctuating levels of apoE proteins, thereby failing to achieve statistical significance.

Several limitations must be considered when interpreting our findings. First, subjects included patients with psychiatric disorders. However, analyzing psychiatric patients and psychiatrically healthy subjects separately also resulted in same findings. Therefore, the influence of psychiatric disorders in a portion of the subjects may be minimal for apoE2/3/4 and TNF-α proteins, although a possibility remains that psychiatric disorder or medication in these subjects contributed to negative results in other proteins. Secondly, the number of homzygotes for APOE-ε4 was so small (n = 1) that we could not examine whether the association occurs in a dose-dependent manner.

In conclusion, APOE-ε4 alleles were associated with increased apoE2, apoE3, and apoE4, as well as decreased TNF-α levels in the CSF of nondemented individuals. Further investigations are warranted to elucidate the role of TNF-α and apoE proteins in the development of APOE-ε4-associated AD.

CONFLICT OF INTEREST
None to declare.

AUTHOR CONTRIBUTIONS
DS and HK designed the study, and DS wrote the draft of the manuscript. KH, YY, RM, TT, and SY retrieved data from the database used in the present study. DS and HK performed statistical analyses. HK supervised the data analysis and writing of the paper. All authors contributed to and have approved the final manuscript.
REFERENCES

1. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131–44.
2. Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM, et al. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):5.
3. Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829–35.
4. Sasayama D, Hattori K, Ogawa S, Yokota Y, Matsumura R, Teraishi T, et al. Genome-wide quantitative trait loci mapping of the human cerebrospinal fluid proteome. Hum Mol Genet. 2017;26(1):44–51.
5. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics (Oxford, England). 2015;31(21):3555–7.
6. Ogawa S, Hattori K, Sasayama D, Yokota Y, Matsumura R, Matsuo J, et al. Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. Sci Rep. 2015;5:7796.
7. Hattori K, Ota M, Sasayama D, Yoshida S, Matsumura R, Miyakawa T, et al. Increased cerebrospinal fluid fibrinogen in major depressive disorder. Sci Rep. 2015;5:11412.
8. Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47(3):401–6.
9. Gold L, Walker JJ, Wilcox SK, Williams S. Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol. 2012;29(5):543–9.
10. Lehtimäki T, Pirttilä T, Mehta PD, Wisniewski HM, Frey H, Nikkari T. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer’s disease. Hum Genet. 1995;95(1):39–42.
11. Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls. Acta Neuropathol. 2014;127(5):633–43.
12. Rezeli M, Zetterberg H, Blennow K, Brinkmalm A, Laurell T, Hansson O, et al. Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer’s disease and other neurodegenerative diseases. EuPA Open Proteomics. 2015;8:137–43.
13. Crucchaga C, Kauwe JSK, Nowotny P, Bales K, Pickering EH, Mayo K, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer’s disease. Hum Mol Genet. 2012;21(20):4558–71.
14. Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamił C, Ahmed H, et al. The apolipoprotein E epsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging. 2011;32(7):1236–48.
15. Candida J, Cheung F, Kotliarov Y, Fantoni G, Sellers B, Griesman T, et al. Assessment of variability in the SOMAscan assay. Sci Rep. 2017;7(1):14248.
16. Chang R, Yee KL, Sumbria RK. Tumor necrosis factor alpha Inhibition for Alzheimer’s disease. J Cent Nerv Syst Dis. 2017:9:1179573517709278.
17. Tarkowski E, Andrewsen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1200–5.
18. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999;19(4):223–30.
19. Laskowitz DT, Goel S, Bennett ER, Matthew WD. Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol. 1997;76(1–2):70–4.
20. Li B, Huang D, Gui L, Qi W, Jia X, Lu B. ApoE gene knockout causes high expressions of TNF-alpha, IL-1beta and IL-8 in mouse brain. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015;31(5):581–4.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Sasayama D, Hattori K, Yokota Y, et al. Increased apolipoprotein E and decreased TNF-α in the cerebrospinal fluid of nondegraded APOE-ε4 carriers. Neurropsychopharmacol Rep. 2020;40:201–205. https://doi.org/10.1002/npr2.12110